|
Patient demographics
|
|
Age at diagnosis (year)
|
13 [12–15]
|
|
Female:male ratio
|
5.6:1
|
|
Ethnicity
|
|
Chinese
|
56 (94.9%)
|
|
Others
|
3 (5.1%)
|
|
Disease duration in years
|
7.8 [5.5–10.1]
|
|
Disease manifestations
|
|
Presence of neuropsychiatric manifestations
|
9 (15.3%)
|
|
Presence of haematological involvement
|
40 (67.8%)
|
|
Presence of renal involvement
|
47 (79.7%)
|
|
WHO class II lupus nephritis
|
2 (3.3%)
|
|
WHO class III lupus nephritis
|
10 (16.9%)
|
|
WHO class IV lupus nephritis
|
30 (50.8%)
|
|
WHO class V lupus nephritis
|
8 (13.6%)
|
|
Presence of serositis
|
10 (16.9%)
|
|
Drug therapies
|
|
Ever use of hydroxychloroquine
|
36 (61%)
|
|
Ever use of intravenous methylprednisolone
|
28 (31.9%)
|
|
Ever use of cyclophosphamide (intravenous or oral)
|
35 (59.3%)
|
|
Ever use of mycophenolate mofetil/mycophenolic acid
|
21 (35.6%)
|
|
Ever use of azathioprine
|
49 (83.1%)
|
|
Ever use of cyclosporine
|
13 (22%)
|
|
Ever use of intravenous immunoglobulin
|
7 (11.9%)
|
|
Ever use of rituximab
|
1 (1.7%)
|
